The combination of talazoparib and quizartinib exerted a strong in vivo inhibitory effect against FLT3-ITDITD;Tet2−/− leukemia, while it was neither effective nor enhanced the effect of the combination in FLT3-ITDITD;Dnmt3a−/− cells. Here, FLT3 is linked to leukemia.